Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -3 of 3
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/11/2007
 
First Published:
7/8/2005
1.
Phase I/II Study of Iodine I 131 Monoclonal Antibody BC8, Fludarabine, and Low-Dose Total Body Irradiation Followed By Allogeneic Peripheral Blood Stem Cell Transplantation and Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
16 to 50
Other
FHCRC-1809.00
5602, NCT00119366
Last Modified:
7/30/2008
 
First Published:
1/1/2001
2.
Phase I Study of Iodine I 131 Monoclonal Antibody BC8 With Low-Dose Total Body Irradiation, Allogeneic Peripheral Blood Stem Cell Infusion, and Immunosuppression With Cyclosporine and Mycophenolate Mofetil in Elderly Patients With Advanced Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, or Chronic Myelomonocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
50 and over
NCI
FHCRC-1432.00
NCI-H00-0066, NCT00008177
Last Modified:
5/21/2008
 
First Published:
12/11/2007
3.
Phase I Study of Iodine I 131 Monoclonal Antibody BC8 and Conditioning Comprising Fludarabine Phosphate,Cyclophophosphamide, and Total-Body Irradiation Followed by Haploidentical Related Allogeneic Bone Marrow Transplantation and Post-Transplant Immunosuppression Comprising Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndromes
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
NCI
FHCRC-2186.00
FHCRC-2186.00, NCT00589316
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute